RSS Feeds
Search

Press releases

Press releases

Displaying 1..6 of 6 - per page
Order by
Ketoprofen Patch clinical efficacy to be officially presented to the rheumatologists associations in USA and France
APR Applied Pharma Research will soon present results of the phase III efficacy trials with ketoprofen patch in the treatment of tendinites and ankle sprains at the annual meetings of the American College of Rheumatology and of the French Society of More
APR Applied Pharma Research and ProEthic sign licensing agreement for the marketing of a Ketoprofen Patch in USA
ProEthic Laboratories, LLC and Applied Pharma Research have signed a licensing agreement for a once-daily transdermal version of ketoprofen, a member of the NSAID class of drugs that also includes the popular Celebrex and Vioxx brands. More
APR PUBLISHES VERY SUCCESSFUL CLINICAL RESULTS ON TISSUE ABSORPTION AND DISTRIBUTION OF KETOPROFEN PATCH IN PATIENTS UNDERGOING KNEE ARTHROSCOPY OR ENDOSCOPIC CARPAL LIGAMENT RELEASE
The Swiss based Drug Delivery Company APR Applied Pharma Research has recently published very successful results on tissue absorption and distribution of ketoprofen TDS patch. More
EUROPEAN MEDICINES EVALUATION AGENCY (EMEA) STATES THAT NIMESULIDE IS SAFE AND EFFECTIVE
EUROPEAN MEDICINES EVALUATION AGENCY (EMEA) STATES THAT NIMESULIDE IS SAFE AND EFFECTIVE More
EULAR Congress, Lisbon 18-21 June 2003: Helsinn Satellite Symposium - The Management of Pain and Inflammation: What is the Role of NSAIDs?
EULAR Congress, Lisbon 18-21 June 2003: Helsinn Satellite Symposium - The Management of Pain and Inflammation: What is the Role of NSAIDs? More
OXAPROZIN: AN INCREASING PERFORMANCE THROUGH NEW MARKET LAUNCHES
OXAPROZIN: AN INCREASING PERFORMANCE THROUGH NEW MARKET LAUNCHES More
Displaying 1..6 of 6 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
National Institute of Arthritis and Musculoskeletal and Skin Diseases – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
National Institute of Arthritis and Musculoskeletal and Skin Diseases – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 84 pages - $500
Epidemiology: Rheumatoid Arthritis - Aging populations behind increases in patient populations
Mar 2011 - 23 pages - $5,700
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Oct 2010 - 169 pages - $3,500
Arthritis Therapy Area Pipeline Report
Nov 2010 - 382 pages - $1,495
Rheumatoid Arthritis - Pipeline Assessment and Market Forecasts to 2017
Nov 2010 - 50 pages - $2,000
Rheumatoid Arthritis Therapy Area Pipeline Report
Nov 2010 - 1168 pages - $1,495
Rheumatoid Arthritis Market Assessment
Sep 2008 - $2,500
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q4 2010
Dec 2010 - 27 pages - $500
Psoriatic Arthritis - Pipeline Review, H2 2011
Sep 2011 - 18 pages - $500
More Related Market Research Reports >>>

Your selection

Therapeutic target
Musculoskeletal del
Skeletal del
Arthritis (non-specific) del
Year
2003 del

Browse By

Industry sector
Academic/Research
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Non-profit org./Government
Pharmaceutical
Research tools
Service

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us